Clinical trials: ASCVD Management
Medical Conditions to be Studied, Dyslipidemia
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States
This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD.
- Conditions
- Medical Conditions to be Studied, Dyslipidemia, ASCVD Management
- Trial name
- NCT02993120
- Where
- 118 sites in United States
- Volunteers
- 5,006 people
- Sponsor
- Amgen
Atherosclerosis Cardiovascular Disease, ASCVD
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD.
- Conditions
- Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
- Trial name
- NCT07303777
- Testing
- ABP-745 Dose A, ABP-745 Dose B, ABP-745 Dose C
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 200 people
- Sponsor
- Atom Therapeutics Co., Ltd
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes
This is an educational outreach to patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) and their primary care and specialist providers to improve use of guideline-recommended…
- Trial name
- NCT04862858
- Testing
- Educational Intervention
- Where
- United States
- Volunteers
- 4,197 people
- Sponsor
- Humana Inc.
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents
Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol…
- Conditions
- Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol
- Trial name
- SPIRIT (NCT04807400)
- Testing
- Inclisiran, Behavioural Support, Background lipid lowering therapy
- Where
- 17 sites in United Kingdom
- Volunteers
- 892 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease, Heart Failure
Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management
This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD).
- Conditions
- Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease
- Trial name
- FLARE (NCT07160829)
- Testing
- No treatment given
- Where
- 4 sites in Australia, India and 2 more
- Volunteers
- 608 people
- Sponsor
- Novo Nordisk A/S
Atherosclerotic Cardiovascular Disease, ASCVD
Managed Access Programs for TQJ230, Pelacarsen
The purpose of this registration is to list Managed Access Programs (MAPs) related to TQJ230, pelacarsen
- Trial name
- NCT07000695
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals